Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Amgen

Status and phase: Completed; Phase 3

Conditions: Immune Thrombocytopenia

Treatments: Drug: Romiplostim

Study type: Interventional

Funder types: Industry

Identifiers

NCT02279173

2011-005019-96 (EudraCT Number)

20101221

Details and patient eligibility

About

This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric participants with ITP have a platelet response while receiving romiplostim, defined as a platelet count ≥ 50 x 10^9/L in the absence of ITP rescue medications for the past 4 weeks.

Enrollment: 203 patients

Sex: All

Ages: 1 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary ITP according to The American Society of Hematology (ASH) Guidelines at least 6 months before screening, regardless of splenectomy status

• Age ≥ 1 year and < 18 years of age

• Refractory to prior ITP therapy, relapsed after at prior ITP therapy, or be ineligible for other therapies. Examples of prior therapy include: corticosteroids, intravenous Immunoglobulin (IVIG), anti-D immunoglobulin, platelet transfusions.

• Platelet count ≤ 30 x10^9/L or is experiencing uncontrolled bleeding

• Has provided informed consent before any study-specific procedure;

• Adequate hematologic, renal, and liver function during screening:

  • Hemoglobin > 10.0 g/dL
  • Serum creatinine ≤ 1.5 x the upper limit of normal (ULN)
  • Total serum bilirubin ≤ 1.5 x the ULN
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x the ULN

• For the EU, Switzerland and Turkey protocol supplement, subject must agree to a scheduled bone marrow biopsy and aspirate at Year 1 or Year 2 following romiplostim treatment and any unscheduled biopsies if clinically indicated

• For the EU, Switzerland and Turkey protocol supplement, a reticulin grade of 0, 1, 2, or 3 according to the modified Bauermeister grading scale, as assessed by central laboratory from a bone marrow biopsy performed within 1 year prior to planned first dose of romiplostim or consent to a pre-treatment bone marrow biopsy and aspirate prior to planned first dose of romiplostim

Exclusion criteria

• History of a bone marrow stem cell disorder (Any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled)
• Prior bone marrow transplant or peripheral blood progenitor cell transplant
• Active or prior malignancy except non-melanoma skin cancers within the last 5 years
• History of myelodysplastic syndrome
• History of bleeding diathesis
• History of congenital thrombocytopenia
• History of Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV)
• History of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia
• History of antiphospholipid antibody syndrome or known positive for lupus anticoagulant
• History of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura
• History of venous thromboembolism or thrombotic events
• Previous use of romiplostim or previous use of eltrombopag within 4 weeks of enrollment
• Previous use of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO) or any other platelet producing agent
• Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or anticipated use at any time during the study
• Splenectomy within 4 weeks of the screening visit
• Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
• Vaccinations known to decrease platelet counts within 8 weeks before the screening visit
• Currently enrolled in another investigational device or drug study, or less than 30 days since ending investigational study
• Will have investigational procedures while enrolled on study
• Female subject of child bearing potential (defined as having first menses) not willing to use, in combination with her partner highly effective methods of birth control during treatment and for 1 month after the end of treatment
• Subject is pregnant or breast feeding, or might become pregnant within 1 month after the end of treatment
• Subject has known hypersensitivity to any recombinant Escherichia coli derived product (eg, Infergen®, Neupogen®, somatropin, and Actimmune®)
• Has previously enrolled into this study
• Will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge
• Any kind of disorder that, may compromise the subject to give written informed consent and/or to comply with all required study procedures

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

203 participants in 1 patient group

Romiplostim

Experimental group

Description:

Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.

Treatment:

Drug: Romiplostim